Sign up to save your podcasts
Or
Share S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
In this episode of the Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internationally recognized expert, discussed advancements in precision oncology, emphasizing the effects of next-generation sequencing and tissue-agnostic therapies on personalized cancer treatment. Dr Subbiah highlighted the transformation in genome sequencing that has taken place since the Human Genome Project, noting the reduction in sequencing costs from $3.3 billion to potentially $1 per genome. He explained how this evolution supports the expansion of precision oncology by making genomic testing accessible across diverse health care settings.
View all episodes
By OncLive® On Air
4.2
2121 ratings
In this episode of the Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internationally recognized expert, discussed advancements in precision oncology, emphasizing the effects of next-generation sequencing and tissue-agnostic therapies on personalized cancer treatment. Dr Subbiah highlighted the transformation in genome sequencing that has taken place since the Human Genome Project, noting the reduction in sequencing costs from $3.3 billion to potentially $1 per genome. He explained how this evolution supports the expansion of precision oncology by making genomic testing accessible across diverse health care settings.
More shows like OncLive® On Air
View all
Wait Wait... Don't Tell Me!
38,677 Listeners
Marketplace Morning Report
903 Listeners
Marketplace
8,659 Listeners
Research To Practice | Oncology Videos
113 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
JAMA Clinical Reviews
493 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
OncoPharm
185 Listeners
ASCO Guidelines
43 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
169 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
39 Listeners
NEJM AI Grand Rounds
54 Listeners